Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company Drug

Zai Lab to Present Zejula OS Study Results at ESMO Congress

Fineline Cube Feb 23, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...

Company Deals

Huadong Medicine Expands Global Partnership with Scohia Pharma for SCO-094

Fineline Cube Feb 23, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) and Japanese firm Scohia Pharma Inc. have announced...

Company Drug

Zai Lab’s SUL-DUR NDA Accepted for Review by NMPA

Fineline Cube Feb 23, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has revealed that a New Drug Application...

Company Deals R&D

Changchun BCHT Biotechnology and IMB CAMS Enter Five-Year Research Pact

Fineline Cube Feb 23, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a five-year scientific research cooperation...

Company Deals

Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca

Fineline Cube Feb 23, 2023

China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have...

Company

Legend Biotech No Longer Faces Delisting from Nasdaq

Fineline Cube Feb 22, 2023

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released a notice stating that it is no...

Company Drug

Abbisko’s ABSK121 Greenlit for Phase I Clinical Study by NMPA

Fineline Cube Feb 22, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving the go-ahead from the...

Company Medical Device

MicroPort CardioFlow’s TAVI Product Approved in Thailand

Fineline Cube Feb 22, 2023

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has...

Company Deals

TransThera Biosciences Completes Series D+ Financing Round

Fineline Cube Feb 22, 2023

China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing...

Company Drug

Shanghai Pharmaceuticals’ WST01 Receives FDA Clinical Clearance

Fineline Cube Feb 22, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced receiving clinical clearance from the...

Company Deals

Huahai Pharma Raises Funds for Digital Manufacturing and API Platform

Fineline Cube Feb 22, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD...

Company Deals R&D

Zai Lab Partners with Sir Run Run Shaw Hospital for Medical Innovation Center

Fineline Cube Feb 22, 2023

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced a strategic partnership agreement...

Company Drug

Huadong Medicine’s Patent Challenge Against Novo Nordisk’s Ozempic Heads to Hearing

Fineline Cube Feb 22, 2023

February 23 will mark the oral hearing phase for the patent challenge case brought by...

Company Drug

Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment

Fineline Cube Feb 22, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and...

Company Drug

Sinovac’s Hepatitis A Vaccine Healive Approved in Egypt

Fineline Cube Feb 22, 2023

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced obtaining market approval from the Egyptian Drug...

Company Medical Device

Asieris’ Uro-G Bladder Endoscope Catheter Awaits NMPA Approval

Fineline Cube Feb 22, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...

Company Deals

Merck KGaA Partners with Beijing for Drug Imports via Beijing Ports

Fineline Cube Feb 22, 2023

Merck KGaA (ETR: MRK), a leading German pharmaceutical company, has struck a partnership with the...

Company Drug

Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials

Fineline Cube Feb 22, 2023

China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...

Company Deals

Meihua International Partners with Hainan for Medical Tech Park and R&D Center

Fineline Cube Feb 22, 2023

Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), a specialist in Chinese medical consumables, has...

Company Deals

Kactus Biosystems and Levinthal Biotech Deepen Strategic Partnership

Fineline Cube Feb 22, 2023

Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a...

Posts pagination

1 … 515 516 517 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.